EyeD Lands $51M to Take Glaucoma Implant Into the Clinic
01/04/2022
EyeD Pharma’s new spin on an old molecule has attracted investor support, giving it 45 million euros ($51 million) to advance an implant that could challenge AbbVie for the glaucoma market, according to a FiercePharma report. EyeD is working on an implant designed to have at least a 2-year duration. The candidate consists of a non-biodegradable intraocular implant that releases timolol, a drug first approved in the 1970s that is still sold as a treatment for open-angle glaucoma and ocular hypertension today.